Abstracts tagged "longitudinal studies"

Abstract Number: 0104 • ACR Convergence 2023
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
Yin Long¹, Jiuliang zhao², Mengtao Li², Xinping Tian² and xiaofeng Zeng³, ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
Abstract Number: 1978 • ACR Convergence 2023
Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative
Kwanghoon Lee¹, Marina Banuls-Mirete², Alecio Lombardi³, Alexander Posis³, Eric Chang³, Nancy Lane⁴ and Monica Guma⁵, ¹Dongguk University ilsan Hospital, San Diego, CA, ²Department of Medicine, University of California San Diego, San Diego, CA, ³University of California San Diego, San Diego, CA, ⁴University of California, Hillsborough, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Adipose tissue is associated with knee osteoarthritis (KOA) progression. This study aimed to determine the association of infrapatellar fat pad (IPFP) size and subcutaneous…
Abstract Number: 0074 • ACR Convergence 2022
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…
Abstract Number: 1553 • ACR Convergence 2022
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Faustino Peron Filho¹, Andressa de Souza Moreira², Anna Larissa Janes² and Alexandre Wagner de Souza², ¹UNIFESP-EPM, Mogi das Cruzes, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil
Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…
Abstract Number: 0138 • ACR Convergence 2022
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Joerg Henes¹, Jasmin B. Kuemmerle-Deschner², Tobias Krickau³, Tilmann Kallinich⁴, Frank Dressler⁵, Gerd Horneff⁶, Florian Meier⁷, Ivan Foeldvari⁸, Frank Weller-Heinemann⁹, Birgit Kortus-Goetze¹⁰, Markus Hufnagel¹¹, Juergen Rech¹², Prasad T. Oommen¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ²Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁶Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁷Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ⁸Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰Division of Nephrology, University of Marburg, Marburg, Germany, ¹¹Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²University Clinic Erlangen, Erlangen, Germany, ¹³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g.…
Abstract Number: 1575 • ACR Convergence 2022
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Larson⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of California Los Angeles, Los Angeles, CA, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵University of South Florida, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka¹, Eisuke Inoue², Kotaro Watanabe³, Mai Abe³, Eri Sugano³, Kumiko Saka³, Moeko Ochiai³, Rei Yamaguchi³, Katsunori Ikari⁴ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Research Administration Center, Showa University, Shinagawa-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, ⁴Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
Abstract Number: 1645 • ACR Convergence 2022
Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Mehreen Soomro¹, Michael Stadler¹, Sebastien Viatte¹, Alex Macgregor², Suzanne Verstappen¹, Anne Barton¹ and John Bowes¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of East Anglia, Norwich, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Eugen Feist¹, Evgeny Nasonov², Michael Luggen³, Saeed Fatenejad⁴, Sergey Grishin⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴SFC Medica, LLC, Charlotte, NC, ⁵R-Pharm, Moscow, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
Abstract Number: 1668 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Alana Bruce¹, Alexander M Menzies², Georgina V Long², Brian Fernandes³ and Fredrick Joshua⁴, ¹Macquarie University, Balaclava, Victoria, Australia, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Macquarie University, Integrated Specialist Medical Care, Sydney, Australia
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
Abstract Number: 0322 • ACR Convergence 2022
Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan², Carolina Munoz², Maria Carmela Tartaglia⁵, Leslet Ruttan⁶, Joan Wither⁷, May Choi⁸, Dennisse Bonilla², Nicole Anderson², Simone Appenzeller⁹, Ben Parker¹⁰, Patricia Katz¹¹, Dorcas Beaton¹², Robin Green⁶, Ian N. Bruce¹³ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Unicamp, Campinas, São Paulo, Brazil, ¹⁰Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹¹UCSF, San Rafael, CA, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Many in-person research studies, such as ours examining cognitive impairment (CI) in SLE, were paused for safety reasons during the COVID-19 pandemic. To restart…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 1784 • ACR Convergence 2022
Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study
Kathryn Bacon¹, David Felson¹, S. Reza Jafarzadeh², Vijaya Kolachalama², Jeffrey Hausdorff³, Eran Gazit⁴, Joshua Stefanik⁵, Patrick Corrigan⁶, Neil Segal⁷, Cora E. Lewis⁸, Michael Nevitt⁹ and Deepak Kumar¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Tel Aviv University, Tel Aviv, Israel, ⁴Tel Aviv Suarasky Medical Center, Tel Aviv, Israel, ⁵Northeastern University, Boston, MA, ⁶Saint Louis University, St. Louis, MO, ⁷University of Kansas, Kansas City, KS, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹University of California at San Francisco, Orinda, CA
Background/Purpose: Altered gait is related to pathogenesis of knee osteoarthritis (OA). For people with knee OA, in addition to pain, declines in physical function are…
Abstract Number: 0342 • ACR Convergence 2022
Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements
Katherine Nay Yaung¹, Joo Guan Yeo², Hui Nee Annie Law³, Martin Wasser⁴, Thaschawee Arkachaisri⁵, Julian Thumboo³, Andrea Low³ and Salvatore Albani⁴, ¹Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore; Duke-NUS Medical School, Singapore, Singapore, ²KK Hospital, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, ³Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁴Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, Singapore, ⁵KK Women's and Children's Hospital, SingHealth, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease that interferes with the balance between regulation and immunity, resulting in immune system dysfunction.…

« Previous Page
1
…
5
6
7
8
9
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].